1
2
3
4
5
6
7
8
9
10
11
12
13 | Licensing Program Analyst (LPA) Avelina Martinez arrived at the facility unannounced on 10/19/2022 at 8:50 am to deliver complaint findings, LPA met with Shane Stumpf and explained the purpose of the visit.
Throughout the course of the investigation, LPA Martinez conducted interviews and reviewed facility records. LPA Martinez reviewed resident 1 (R1) medication orders, medication list, and Medication Administration Record (MAR), and Centrally Stored Medication And Destruction Record (CSMDR). The facility CSMDR record logged Amlodipine 5MG was filled January 27, 2022 and no start date. LPA Martinez reviewed R1's April 2022 Medication list, which stated Amlodipine 5MG. LPA Martinez reviewed R1's May MAR, which stated Amlodipine 2.5 MG and the first part of the May Mar was not completed. Furthermore, there was no discontinuance order for the 5MG and no start order for the 2.5 MG in May of 2022. However, a September 9, 2022 medical doctor order states Amlodipine dosage was changed to 2.5 MG. In addition, facility email correspondence reports R1's Amlodipine dosage was changed to 2.5 MG in September of 2022.
Continued..
|